The KDM1A antibody is a crucial tool in epigenetic research, targeting the lysine-specific demethylase 1A (KDM1A/LSD1), a flavin-dependent enzyme that removes methyl groups from histone H3 lysine 4 (H3K4) and lysine 9 (H3K9). Discovered in 2004. KDM1A regulates gene expression by modifying chromatin structure, playing roles in cell differentiation, proliferation, and oncogenesis. It interacts with transcriptional repressors (e.g., CoREST) and activators, enabling context-dependent gene silencing or activation. Dysregulation of KDM1A is linked to cancers, neurological disorders, and developmental defects, making it a therapeutic target.
KDM1A antibodies are widely used in techniques like Western blotting, immunohistochemistry, ChIP-seq, and immunofluorescence to study its expression, localization, and molecular interactions. High-quality antibodies must demonstrate specificity, as KDM1A shares structural homology with other amine oxidases. Validated antibodies help explore its role in stem cell biology, cancer metastasis, and neurodegenerative diseases. Recent studies also highlight its involvement in immune regulation and metabolic pathways.
Commercial KDM1A antibodies are typically raised against epitopes in its N-terminal SWIRM domain, C-terminal amine oxidase domain, or unique peptide sequences. Researchers prioritize antibodies verified in knockout models or siRNA-treated cells to avoid cross-reactivity. As KDM1A inhibitors enter clinical trials, reliable antibodies remain essential for biomarker analysis and mechanistic studies, underscoring their significance in both basic research and translational medicine.